<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03045510</url>
  </required_header>
  <id_info>
    <org_study_id>lower risk MDS-decitabine</org_study_id>
    <nct_id>NCT03045510</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent</brief_title>
  <official_title>A Single-center Prospective Clinical Trial of the Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk Myelodysplastic Syndrome Patients With Transfusion Dependent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myelodysplastic syndrome (MDS) is widely recognized as a clonal hematopoietic stem cell&#xD;
      disorder. Decitabine has been approved for the treatment of all subtypes of myelodysplastic&#xD;
      syndrome (MDS). However, the use of decitabine is often limited by its severe toxicity&#xD;
      represented by myelosuppression even at relatively low doses. In lower-risk patients&#xD;
      (including IPSS low and int-1 risk groups), treatment mainly aims at improving cytopenias,&#xD;
      especially anemia. However, although several drugs may improve anemia, sometimes durably,&#xD;
      most of lower risk MDS eventually require red blood cell (RBC) transfusions during their&#xD;
      disease course. Long term RBC transfusions lead to iron overload mainly due to an increase in&#xD;
      reticulo-endothelial iron recycling.Cardiac, liver and endocrine (diabetes mellitus)&#xD;
      dysfunction due to iron overload and often leading to fatal outcome has been reported in&#xD;
      heavily transfused lower risk MDS patients.&#xD;
&#xD;
      To date, the optimal regimen for decitabine treatment is not well established. In this study,&#xD;
      we perform a prospective analysis to explore the decitabine schedule for the treatment of&#xD;
      lower risk myelodysplastic syndrome patients with transfusion dependent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are undertaking a single-center, single-arm study of 50 lower risk&#xD;
      myelodysplastic syndrome patients with transfusion dependent from Shandong University Qilu&#xD;
      Hospital . All the participants are selected to receive ultra small dose decitabine treatment&#xD;
      (given intravenously at a dose of 3.5mg/m2, qd x 5d, every four weeks for one cycle). A&#xD;
      routine blood examination is performed twice every week. Bone marrow (BM) is examined with&#xD;
      routine aspirate smear and G-banding analysis every 1-2 treatment courses to evaluate&#xD;
      responses.Adverse events are also recorded throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response</measure>
    <time_frame>30 days from the emrollment</time_frame>
    <description>Bone marrow blasts not more than 5%, absolute neutrophil count more than 1*10^9/L, HgB more than 100g/L, and platelet count more than 100*10^9/L.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Ultra small dose decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine</intervention_name>
    <description>Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.</description>
    <arm_group_label>Ultra small dose decitabine</arm_group_label>
    <other_name>ultra small dose decitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of MDS&#xD;
&#xD;
          -  The IPSS [17] score ≤ 1&#xD;
&#xD;
          -  patients with transfusion dependent&#xD;
&#xD;
          -  Adequate hepatic and renal function (aspartate aminotransferase [AST] ≤ 2.5 x upper&#xD;
             normal limit, alanine aminotransferase [ALT] ≤ 2.5 x upper normal limit, bilirubin ≤&#xD;
             1.5 x upper normal limit and creatinine &lt; 2 x upper normal limit, Ccr &gt; 60ml/min ).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Decitabine and Arsenic trioxide allergy&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Cardiovascular disease&#xD;
&#xD;
          -  ECOG score &gt; 2&#xD;
&#xD;
          -  HCV, HIV, HBsAg seropositive status&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Lv, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hou Ming</last_name>
    <email>houming@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qilu hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Hou</last_name>
      <email>houming@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Ming Hou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong University Qilu Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Lv</last_name>
    </contact>
    <investigator>
      <last_name>Ming Hou, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>February 3, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Ming Hou</investigator_full_name>
    <investigator_title>Professor and Director</investigator_title>
  </responsible_party>
  <keyword>Decitabine Myelodysplastic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

